Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Monday session in green amid volatile trading. The shares closed up +0.37 points or 0.86% at $43.28 with 2,559,309 shares getting traded. Post opening the session at $43.08, the shares hit an intraday low of $43.00 and an intraday high of $43.32 and the price vacillated in this range throughout the day. The company has a market cap of $103.62 billion and the numbers of outstanding shares have been calculated to be 4.87 billion shares.
GlaxoSmithKline plc (ADR) (GSK) on February 22, 2016 announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has completed two previously announced transactions with Bristol-Myers Squibb to acquire its late-stage HIV R&D assets and its portfolio of preclinical and discovery stage HIV research assets. The completion of both transactions follows antitrust approval by the relevant regulatory authorities in the US, with the integration process beginning immediately.
Dominique Limet, CEO, ViiV Healthcare, said: “As a result of these transactions, ViiV Healthcare now has one of the most robust HIV pipelines in the industry. The assets that we have acquired complement our existing portfolio and could lead to new medicines and combinations addressing a broad range of treatment and prevention needs of people living with HIV.”
Under the terms of the transactions, ViiV Healthcare acquired late-stage HIV R&D assets from Bristol-Myers Squibb for an initial upfront payment of $317 million followed by development and first commercial sale milestones of up to $518M, and tiered royalties on sales. ViiV Healthcare also acquired Bristol-Myers Squibb’s preclinical and discovery stage HIV research business for an upfront payment of $33 million, followed by development and first commercial sales milestones of up to $587M, and further consideration contingent on future sales performance.
ViiV Healthcare has acquired:
- Late stage assets, including fostemsavir (BMS-663068), an attachment inhibitor currently in phase III development for heavily treatment experienced patients. Fostemsavir has received a Breakthrough Therapy Designation from the FDA and is expected to be filed for regulatory approval in 2018. The second late stage asset is a maturation inhibitor (BMS-955176), and is currently in phase IIb development for both treatment-naive and treatment experienced patients. A back-up maturation inhibitor candidate (BMS-986173) is also included in the purchase.
- Assets in preclinical and discovery phases of development including a novel biologic (BMS-986197) with a triple mechanism of action, an additional maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com
Shares of HCA Holdings Inc (NYSE:HCA) ended Monday session in green amid volatile trading. The shares closed up +0.55 points or 0.68% at $81.17 with 3,598,367 shares getting traded. Post opening the session at $80.60, the shares hit an intraday low of $79.43 and an intraday high of $81.24 and the price vacillated in this range throughout the day. The company has a market cap of $31.60 billion and the numbers of outstanding shares have been calculated to be 395.77 million shares.
HCA Holdings Inc (HCA) on April 28, 2016 announced that Charles (“Chad”) O. Holliday, Jr. has been elected as a new independent director of HCA’s board of directors.
Mr. Holliday has served as chairman of Royal Dutch Shell plc since May 2015 and also serves as chairman of The National Academy of Engineering. He is also a director of CH2M HILL Companies, Ltd., a civil engineering firm. He worked for DuPont for 37 years, including serving as chief executive officer from 1998 to 2008 and chairman from 1999 to 2009. He is the former chairman of the US Council on Competitiveness and The World Business Council for Sustainable Development. He was appointed chairman of the Executive Committee, Sustainable Energy for ALL by the Secretary General of the United Nations and is a member of The American Academy of Arts and Sciences.
- Milton Johnson, chairman and chief executive officer of HCA, commented, “We are excited to have Chad joining our board of directors. I am confident that HCA will benefit greatly from his extensive U.S. and international business leadership experience.”
Shares of Opko Health Inc. (NYSE:OPK) ended Monday session in red amid volatile trading. The shares closed down -0.29 points or -2.70% at $10.46 with 4,791,876 shares getting traded. Post opening the session at $10.80, the shares hit an intraday low of $10.15 and an intraday high of $10.80 and the price vacillated in this range throughout the day. The company has a market cap of $5.66 billion and the numbers of outstanding shares have been calculated to be 545.84 million shares.
Opko Health Inc. (OPK) announced that it will release operating and financial results for the three months ended March 31, 2016, after the close of the U.S. financial markets on Monday, May 9, 2016.
OPKO’s senior management will provide a business update and discuss its results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Monday, May 9, 2016.
The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
CONFERENCE CALL & WEBCAST INFORMATION
WHEN: Monday, May 9, 2016, 4:30 p.m. ET
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 2590322
For those unable to participate in the conference call or webcast, a replay will be available beginning May 9, 2016 at 7:30 p.m. ET until May 15, 2016 at 11:59 p.m. ET. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 2590322.
The replay can also be accessed for a period of time on OPKO’s website at www.opko.com.